Scientist
INVESTORS
2019-02-07MMMM D, YYYY

Fourth quarter and full year 2018 results

At a glance

Jean-Baptiste de Chatillon
2019-04-30MMMM D, YYYY

Annual General Meeting 2019

Find all information about the Annual General Meeting 2019

2017 Integrated Report

2018 Integrated Report

Upcoming events

All financial results going back to 2013
FINANCIAL RESULTS

All financial results going back to 2013

Annual Report on Form 20-F 2018

Annual Report on Form 20-F 2018

Contact the Investor Relations team

54 rue La Boétie
75008 Paris FRANCE
France +33 (0)1 53 77 45 45 • ir@sanofi.com
United States +1 908 981 5560

Press releases

[Feed JS]

In-depth reading

Young boy on a bicycle

New franchise Rare Blood Disorders

In 2018, Sanofi created a leading platform in Rare Blood Disorders through a series of three strategic deals: we obtained global rights for fitusiran, acquired Bioverativ and Ablynx. These operations should expand Sanofi’s presence in Specialty Care and further strengthen our Research & Development pipeline.
Scientist
FINANCIAL RESULTS

2018 sales reflecting 2019 GBU structure

2019-02-07MMMM D, YYYY
Digital factory

The digital revolution

INVESTOR PRESENTATIONS

IR conference call on Odyssey Outcomes

2018-03-10MMMM D, YYYY
sanofi_ir_2017_ddr_bloc_vertical

Annual Report on Form 20-F 2017

Individual shareholders

Direct access to Individual shareholders - Welcome to Sanofi

Access your dedicated section

2017 Sanofi Brochure

Shareholder Handbook 2018

Two Asian women

Letter to shareholders March 2019

Sanofi IR app on different devices

SANOFI IR The Investor Relations app

SANOFI IR provides financial information with direct access to key news, events, publications and a dedicated section for individual shareholders
Download the IR app on the App Store Get the IR app on Google Play